Chengdu Baishixing Science and Technology Industry Co., Ltd.

Chengdu Baishexing Technology Industrial Co., Ltd., relying on 39 patent and copyright technologies as its technical support and with an annual production capacity of over 1,000 tons, has established a core product matrix of five categories: culture medium series, amino acids and their derivatives series, protective amino acids series, pharmaceutical intermediates series, and other supporting products. All products are strictly benchmarked against Chinese Pharmacopoeia, US Pharmacopoeia, European Pharmacopoeia, Japanese Pharmacopoeia, and Yuki Suisou standards. They are produced in accordance with GMP standards through the entire production process control. They are widely applied in multiple fields such as biomedicine, cell therapy, pharmaceutical research and development, agriculture, and high-end food. It is a long-term core supplier for international enterprises such as Pfizer, Thermo Fisher, and Merck Pharmaceuticals. The culture medium series is centered on digoxin and glycyl-L-tyrosine, serving as key nutritional raw materials for cell culture in antibody drug, gene therapy, and vaccine production, and can efficiently support cell growth and protein expression. The amino acids and their derivatives series covers over 100 products such as D-type amino acids, L-tyrosine disodium, and tert-butoxyglycine hydrochloride salt. The self-developed production process of tyrosine disodium fills the domestic gap. It is suitable for scenarios such as peptide synthesis and preparation of pharmaceutical intermediates. The protective amino acids series focuses on Fmoc, Boc, CBZ series, and side chains of teriparatide and semaglutide, serving as core raw materials for the synthesis of peptide drugs such as weight loss, diabetes, and Alzheimer's disease. The pharmaceutical intermediates series includes core products such as whey acid and halichondrin. The bromine-free production process of whey acid realizes nearly zero bromine residue and a purity of over 99.5%, and the one-pot production process of halichondrin significantly reduces energy consumption. Several innovative drug core materials have entered the second and third phases of clinical trials. Other supporting products include heterocyclic compounds, plant growth regulators, and vitamins. Vitamin B13 and agricultural amino acid derivatives respectively occupy 70% and 80% of the global market share, possessing global market discourse power and pricing power. They can fully meet the multi-dimensional raw material demands of customers from laboratory small-scale trials to industrial production.